HK1079435A1 - Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy - Google Patents

Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy

Info

Publication number
HK1079435A1
HK1079435A1 HK05111475A HK05111475A HK1079435A1 HK 1079435 A1 HK1079435 A1 HK 1079435A1 HK 05111475 A HK05111475 A HK 05111475A HK 05111475 A HK05111475 A HK 05111475A HK 1079435 A1 HK1079435 A1 HK 1079435A1
Authority
HK
Hong Kong
Prior art keywords
nephropathy
fro
medicaments
preparations
treatment
Prior art date
Application number
HK05111475A
Other languages
English (en)
Inventor
Schaefer Stefan
Linz Wolfgang
Bleich Markus
Huber Jochen
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1079435A1 publication Critical patent/HK1079435A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK05111475A 2002-06-28 2005-12-14 Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy HK1079435A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
PCT/EP2003/006276 WO2004002492A1 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy

Publications (1)

Publication Number Publication Date
HK1079435A1 true HK1079435A1 (en) 2006-04-07

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111475A HK1079435A1 (en) 2002-06-28 2005-12-14 Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy

Country Status (39)

Country Link
US (2) US6930103B2 (de)
EP (1) EP1519732B1 (de)
JP (1) JP4564354B2 (de)
KR (1) KR101072235B1 (de)
CN (1) CN100366254C (de)
AR (1) AR040343A1 (de)
AT (1) ATE548040T1 (de)
AU (1) AU2003280440B2 (de)
BR (1) BR0312250A (de)
CA (1) CA2490277C (de)
CR (1) CR7667A (de)
CY (1) CY1112905T1 (de)
DE (1) DE10229180A1 (de)
DK (1) DK1519732T3 (de)
EC (1) ECSP045513A (de)
ES (1) ES2383889T3 (de)
HK (1) HK1079435A1 (de)
HN (1) HN2003000193A (de)
HR (1) HRP20041212B1 (de)
IL (2) IL165935A0 (de)
MA (1) MA27281A1 (de)
MX (1) MXPA04012230A (de)
NO (1) NO334811B1 (de)
NZ (1) NZ537480A (de)
OA (1) OA12871A (de)
PA (1) PA8576501A1 (de)
PE (1) PE20040582A1 (de)
PL (1) PL218070B1 (de)
PT (1) PT1519732E (de)
RS (1) RS52478B (de)
RU (1) RU2336080C2 (de)
SI (1) SI1519732T1 (de)
SV (1) SV2004001560A (de)
TN (1) TNSN04262A1 (de)
TW (1) TWI326215B (de)
UA (1) UA82845C2 (de)
UY (1) UY27869A1 (de)
WO (1) WO2004002492A1 (de)
ZA (1) ZA200409382B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69211133T2 (de) * 1991-03-01 1996-10-31 Zeria Pharmaceutical Co., Ltd., Tokio/Tokyo Indan-derivate als thromboxan-antagonisten
CA2078758C (en) * 1991-09-27 2003-12-09 Alan M. Warshawsky 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69317764T2 (de) * 1992-02-14 1998-07-30 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
JPH09510476A (ja) * 1994-03-24 1997-10-21 メリル・フアーマシユウテイカルズ・インコーポレイテツド 低コレステロール血性、抗アテローム性動脈硬化性および低トリグリセライド血性のアミノアセチルメルカプト誘導体
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
EE03524B1 (et) 1995-12-27 2001-10-15 Yoshitomi Pharmaceutical Industries, Ltd. Vahend diabeedi komplikatsioonide profülaktikaks ja raviks
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
CZ299708B6 (cs) * 2001-04-12 2008-10-29 Sanofi - Aventis Deutschland GmbH Merkaptoacetylamidové deriváty, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem k ošetrování kardiovaskulárních onemocnení
AU2002355419A1 (en) * 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
HRP20041212A2 (en) 2005-06-30
DK1519732T3 (da) 2012-06-18
AU2003280440B2 (en) 2009-07-16
CN1665512A (zh) 2005-09-07
DE10229180A1 (de) 2004-01-29
MXPA04012230A (es) 2005-02-25
PA8576501A1 (es) 2004-02-07
NO334811B1 (no) 2014-06-02
CY1112905T1 (el) 2016-04-13
ECSP045513A (es) 2005-03-10
TWI326215B (en) 2010-06-21
MA27281A1 (fr) 2005-04-01
HRP20041212B1 (hr) 2013-06-30
OA12871A (en) 2006-09-15
IL165935A0 (en) 2006-01-15
CN100366254C (zh) 2008-02-06
BR0312250A (pt) 2005-04-26
TNSN04262A1 (en) 2007-03-12
JP2005533815A (ja) 2005-11-10
US20040058911A1 (en) 2004-03-25
RS52478B (en) 2013-02-28
EP1519732B1 (de) 2012-03-07
CA2490277A1 (en) 2004-01-08
SI1519732T1 (sl) 2012-05-31
SV2004001560A (es) 2004-02-26
TW200406214A (en) 2004-05-01
KR101072235B1 (ko) 2011-10-12
CR7667A (es) 2005-06-16
ZA200409382B (en) 2006-01-25
PE20040582A1 (es) 2004-10-18
CA2490277C (en) 2011-11-01
UA82845C2 (en) 2008-05-26
KR20050013642A (ko) 2005-02-04
US6930103B2 (en) 2005-08-16
ES2383889T3 (es) 2012-06-27
HN2003000193A (es) 2004-10-27
ATE548040T1 (de) 2012-03-15
AU2003280440A1 (en) 2004-01-19
PL218070B1 (pl) 2014-10-31
US7514423B2 (en) 2009-04-07
JP4564354B2 (ja) 2010-10-20
EP1519732A1 (de) 2005-04-06
NZ537480A (en) 2005-11-25
AR040343A1 (es) 2005-03-30
PL372992A1 (en) 2005-08-08
US20050171090A1 (en) 2005-08-04
UY27869A1 (es) 2003-12-31
PT1519732E (pt) 2012-05-22
IL165935A (en) 2010-12-30
WO2004002492A1 (en) 2004-01-08
NO20050425L (no) 2005-01-25
RS100704A (en) 2007-02-05
RU2336080C2 (ru) 2008-10-20
RU2005102087A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
IL172316A0 (en) Novel compounds and their use in therapy
AU2003265225A8 (en) Preparations for topical skin use and treatment
AU2003213768A8 (en) Use of benzimidazole analogs in the treatment of cell proliferation
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
AU2003293376A8 (en) Anti-angiogenic compounds and their use in cancer treatment
HK1162948A1 (zh) 哈米特林 衍生物及其在治療癌症中的應用
HK1097256A1 (en) Pyrizdazine derivatives and their use as therapeutic agents
GB0324761D0 (en) Use of compounds in therapy
HK1080447B (zh) 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
EP1515725A4 (de) Verwendung von cyclothiocarbamat-derivativen bei der behandlung von hormonabhängigen erkrankungen
IL165394A0 (en) Use of thio-oxindole derivatives in treatment of skin disorders
GB0207411D0 (en) Azole compounds and their therapeutic use
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
GB0207410D0 (en) Compounds and their therapeutic use
SG110107A1 (en) Compound and use in treatment
HK1079435A1 (en) Use of vasopeptidase inhibitors in the preparations of medicaments fro the treatment of nephropathy
EP1666046A4 (de) Verwendung von n-acetyl-d-aminoglycosamin bei der herstellung von arzneimitteln zur behandlung von krebs und metastasen
AU2003215767A8 (en) Devices for use in medicine
EP1583543A4 (de) Verfahren und therapeutische zusammensetzungen bei der behandlung fortgeschrittener karzinome
IL175774A0 (en) Use of siramesine in the treatment of cancer
GB0207409D0 (en) Benzofuran-2H-3-one compounds and their therapeutic use

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20060407: [71] SANOFI-AVENTIS DEUTSCHLAND GMBH - D-65929FRANKFURT AM MAIN - GERMANY

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150613